# A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke

> **NCT01605825** · PHASE2 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 83 (actual)

## Conditions studied

- Ischemic Stroke

## Interventions

- **DRUG:** placebo/dalfampridine-ER
- **DRUG:** dalfampridine-ER/placebo

## Key facts

- **NCT ID:** NCT01605825
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-02
- **Final completion:** 2013-03
- **Target enrollment:** 83 (ACTUAL)
- **Last updated:** 2016-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01605825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01605825, "A Phase 2b Study of Dalfampridine 10mg Extended Release Tablet in Subjects With Chronic Deficits After Ischemic Stroke". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01605825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*